Novartis | NOVN - Pre Tax Profit


Novartis reported $4.27B in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Alcon AG USD 240M 24M Mar/2026
Almirall EUR 30.32M 22M Dec/2025
Amgen USD 2.08B 570M Mar/2026
AstraZeneca USD 4.81B 894M Jun/2026
Autolus Therapeutics Ltd USD -70.73M 20.78M Mar/2026
Bayer EUR 321M 2.67B Jun/2026
Biogen USD 647.3M 269.6M Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Fresenius EUR 535M 42M Jun/2026
Fresenius Medical Care EUR 383M 43M Jun/2026
Genmab DKK 295M 221M Jun/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
GRIFOLS EUR 247M 135M Jun/2026
Hikma Pharmaceutical USD 147.5M 3.5M Jun/2025
J&J USD 8.66B 839M Jun/2026
Lakefront Biotherapeutics EUR 13.96M 769.2M Mar/2026
Lonza CHF 624M 197M Dec/2024
Merck EUR 869M 468M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novartis USD 3.84B 1.33B Mar/2026
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Orion EUR 113.4M 213.6M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Philips EUR 546M 356M Jun/2026
Recordati EUR 161.16M 39.6M Jun/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sanofi EUR 837M 1.17B Jun/2026
UCB EUR 789M 427M Jun/2025